Acute Spinal Cord Injury - Drug Pipeline Landscape, 2023
Description
Acute Spinal Cord Injury - Drug Pipeline Landscape, 2023
Acute Spinal Cord Injury is a condition of damage to any part of the spinal cord or nerves at the end of the spinal canal cauda equina. The injury may cause a contusion, a partial tear or a complete tear transection in the spinal cord.
Causes of acute spinal cord injury are damage to the vertebrae, ligaments or disks of the spinal column or to the spinal cord itself.
Symptoms of acute spinal cord injury includes weakness in the arms and or legs, difficulty breathing, severe pain or pressure in the neck or back, decreased sensation in the arms and or legs, unusual lumps along the spine, loss of bladder or bowel control.
Acute Spinal Cord Injury is diagnosed by tests like X-rays, computerized tomography (CT) scan and magnetic resonance imaging (MRI).
Treatment for acute spinal cord injury includes surgery, medication like corticosteroid injections and physical therapy.
There are several companies active in the development of acute spinal cord injury drugs, including AbbVie., AlaMab Therapeutics (Shanghai) Inc, Athersys Inc, and Axoltis Pharma SAS.
There are many clinical trials ongoing in Acute Spinal Cord Injury Drug Development. Some of the most promising trials are studying the use of stem cells to repair the damaged spinal cord. Other trials are investigating the use of drugs to reduce inflammation and improve nerve function.
Report Highlights
Global Insight Service’s, Acute Spinal Cord Injury - Drug Pipeline Landscape, 2023 report provides an overview of the Acute Spinal Cord Injury pipeline drugs. This report covers detailed insights on Acute Spinal Cord Injury drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Acute Spinal Cord Injury pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Acute Spinal Cord Injury is a condition of damage to any part of the spinal cord or nerves at the end of the spinal canal cauda equina. The injury may cause a contusion, a partial tear or a complete tear transection in the spinal cord.
Causes of acute spinal cord injury are damage to the vertebrae, ligaments or disks of the spinal column or to the spinal cord itself.
Symptoms of acute spinal cord injury includes weakness in the arms and or legs, difficulty breathing, severe pain or pressure in the neck or back, decreased sensation in the arms and or legs, unusual lumps along the spine, loss of bladder or bowel control.
Acute Spinal Cord Injury is diagnosed by tests like X-rays, computerized tomography (CT) scan and magnetic resonance imaging (MRI).
Treatment for acute spinal cord injury includes surgery, medication like corticosteroid injections and physical therapy.
There are several companies active in the development of acute spinal cord injury drugs, including AbbVie., AlaMab Therapeutics (Shanghai) Inc, Athersys Inc, and Axoltis Pharma SAS.
There are many clinical trials ongoing in Acute Spinal Cord Injury Drug Development. Some of the most promising trials are studying the use of stem cells to repair the damaged spinal cord. Other trials are investigating the use of drugs to reduce inflammation and improve nerve function.
Report Highlights
Global Insight Service’s, Acute Spinal Cord Injury - Drug Pipeline Landscape, 2023 report provides an overview of the Acute Spinal Cord Injury pipeline drugs. This report covers detailed insights on Acute Spinal Cord Injury drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Acute Spinal Cord Injury pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
108 Pages
- 1. Introduction
- 1.1 Acute Spinal Cord Injury – Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview – Acute Spinal Cord Injury
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Acute Spinal Cord Injury – Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs - Phase III
- 5.1.1 ES135
- 5.1.2 KP-100IT
- 5.1.3 Nabiximols
- 5.1.4 Neuro-Cells
- 5.2 Clinical Stage Drugs - Phase II
- 5.2.1 Elezanumab
- 5.2.2 FAB117-HC
- 5.2.3 MT-3921
- 5.2.4 OPC 1
- 5.2.5 PSA-NCAM(+) Neural Precursor Cells
- 5.2.6 Sovateltide
- 5.3 Clinical Stage Drugs - Phase I
- 5.3.1 ALMB-0166
- 5.3.2 GM603
- 5.3.3 NVG-291
- 5.4 Early Stage Drugs - Preclinical
- 5.4.1 Bioengineered Stem Cells
- 5.4.2 Bone Marrow Mesenchymal Stem Cells
- 5.4.3 CX1739
- 5.4.4 CX717
- 5.4.5 Human Amniotic Epithelial Stem Cells
- 5.4.6 KAND567
- 5.4.7 Multi Stem cell therapy
- 5.4.8 NCP-01
- 5.4.9 NG004
- 5.4.10 NOVO-118
- 5.4.11 NX210c
- 5.5 Clinical Stage Drugs - Discovery
- 5.5.1 CLZ-2002/T-SC
- 5.5.2 CX1942
- 5.5.3 Gene Therapy
- 5.5.4 HNPC-02
- 5.5.5 OligoGenie
- 5.5.6 Stem Cell Therapy for Spinal Cord Injury
- 5.5.7 Stem Cells
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 AbbVie
- 9.2 AlaMab Therapeutics (Shanghai) Inc
- 9.3 Athersys Inc
- 9.4 Axoltis Pharma SAS
- 9.5 Cellatoz Therapeutics Inc
- 9.6 Eusol Biotech
- 9.7 Ferrer Internacional S.A
- 9.8 Genervon Biopharmaceuticals LLC
- 9.9 Hemostemix Inc
- 9.10 Hopstem Biotechnology LLC
- 9.11 ICELL Biotechnology Co Ltd
- 9.12 Inteligex
- 9.13 Invivo Therapeutics
- 9.14 Jazz Pharmaceuticals Plc
- 9.15 Kancera
- 9.16 Kidswell Bio Corp
- 9.17 Kringle Pharma Inc
- 9.18 Lineage Cell Therapeutics
- 9.19 Mitsubishi Tanabe Pharma Development America Inc
- 9.20 Nergen Pharma
- 9.21 NeuExcell Therapeutics Inc
- 9.22 Neurimmune
- 9.23 Neuroplast
- 9.24 Novoron Bioscience Inc
- 9.25 Oligogen Inc
- 9.26 Pharmazz Inc
- 9.27 RespireRx Pharmaceuticals Inc
- 9.28 S.Biomedics Co Ltd
- 9.29 Shenzhen Toyon Biotechnology Co Ltd
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products Under Development for Acute Spinal Cord Injury
- Table 1.2 Number of Products Under Development by Companies
- Table 1.3 Products Under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 1.2 Number of Products Under Development by Companies
- Table 1.3 Products Under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - KP-100IT/Kringle Pharma Inc
- Table 2.2 Clinical Trial Details - ALMB-0166/AlaMab Therapeutics (Shanghai) Inc
- Table 2.3 Clinical Trial Details - Sovateltide/Pharmazz Inc
- Table 2.4 Clinical Trial Details - Neuro-Cells/Neuroplast
- Table 2.5 Clinical Trial Details - FAB117-HC/Ferrer Internacional S.A
- Table 2.6 Clinical Trial Details - PSA-NCAM(+) Neural Precursor Cells/S.Biomedics Co Ltd
- Table 2.7 Clinical Trial Details - Elezanumab/AbbVie
- Table 2.8 Clinical Trial Details - MT-3921/Mitsubishi Tanabe Pharma Development America Inc
- Table 2.9 Clinical Trial Details - OPC 1/Lineage Cell Therapeutics
- Table 2.10 Clinical Trial Details - ES135/Eusol Biotech
- Table 2.11 Clinical Trial Details - NVG-291/Nergen Pharma
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products Under Development for Acute Spinal Cord Injury, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Acute Spinal Cord Injury, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action for Acute Spinal Cord Injury, 2023
- Figure 1.4 Products by Top 5 Molecule Type for Acute Spinal Cord Injury, 2023
- Figure 1.5 Products by Top 5 Route of Administration for Acute Spinal Cord Injury, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
